Watch CTRVP. Know when insiders buy.
One email the day a filing lands. Free.
CTRVP
Hepion Pharmaceuticals, Inc.
0.00
+0.00 +0.00%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $117KP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$3.2MNET CASH $13.7M52W 0.00 – 0.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$1.2M | −$1.2M | — | -0.08 | −$1.4M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$799K | −$811K | — | -0.07 | $579K | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$610K | −$657K | — | 0.00 | −$333K | — | — | Mar 12 |
| Q3 2025 · Sep 30 | — | — | — | −$528K | −$473K | — | -0.04 | −$446K | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$1.7M | −$1M | — | -0.09 | −$1.4M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$1.3M | −$6.1M | — | -2.15 | −$1.1M | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$1.2M | −$1.5M | — | -8.17 | −$1.2M | — | — | Mar 12 |
| Q3 2024 · Sep 30 | — | — | — | −$4.5M | −$4.9M | — | -36.21 | −$2.5M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$8.5M | −$3.9M | — | -34.00 | −$10.9M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | $0 | — | — | −$5.2M | −$2.9M | — | -28.13 | −$3.6M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$10.4M | −$11.1M | — | -606.17 | −$9M | $348 | −$9M | Apr 8 |
| Q3 2023 · Sep 30 | $0 | — | — | −$10.7M | −$10.5M | — | -2.74 | −$11.2M | −$3K | −$11.2M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$4.2M | −$8.3M | — | -0.88 | −$3.3M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$19.3M | −$13.2M | — | -107.35 | −$18.2M | — | — | — | — |
| FY2023 · to Dec 31 | $0 | — | −$48.4M | −$48.9M | — | -616.07 | −$40.9M | $14K | −$40.9M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$45.5M | −$42.2M | — | -11.90 | −$35M | $16K | −$35M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$30.4M | −$32.7M | — | -0.47 | −$31.2M | $130K | −$31.4M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$20.1M | −$20.4M | — | -2.10 | −$16.2M | $88K | −$16.3M | — | — |
Every number comes from Hepion Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.